OverviewSuggest Edit

GBT (Global Blood Therapeutics) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. The Company develops its lead product candidate, voxelotor, as an oral, once-daily therapy for sickle cell disease. It is also investigating GBT440 for the treatment of hypoxemic pulmonary disorders in an ongoing Phase 2a study in patients with idiopathic pulmonary fibrosis.

TypePublic
Founded2012
HQSouth San Francisco, CA, US
Websitegbt.com
Employee Ratings4.5

Latest Updates

Employees (est.) (Dec 2019)352(+106%)
Job Openings55
Revenue (FY, 2020)$123.8 M(+5774%)
Share Price (Sept 2021)$26.3(-3%)
Cybersecurity ratingAMore

Key People/Management at GBT (Global Blood Therapeutics)

Ted W. Love

Ted W. Love

President and Chief Executive Officer
Jung E. Choi

Jung E. Choi

Chief Business and Strategy Officer
Jeffrey Farrow

Jeffrey Farrow

Chief Financial Officer
Nazila Habibizad

Nazila Habibizad

Senior Vice President, Operations
Carrie Krehlik

Carrie Krehlik

Chief Human Resources Officer
David L. Johnson

David L. Johnson

Chief Commercial Officer
Show more

GBT (Global Blood Therapeutics) Office Locations

GBT (Global Blood Therapeutics) has offices in South San Francisco and Zug
South San Francisco, CA, US (HQ)
171 Oyster Point Blvd #300South
Zug, CH
Grafenauweg 8
Show all (2)

GBT (Global Blood Therapeutics) Financials and Metrics

GBT (Global Blood Therapeutics) Revenue

GBT (Global Blood Therapeutics)'s revenue was reported to be $123.8 m in FY, 2020
USD

Revenue (FY, 2020)

123.8m

Gross profit (FY, 2020)

121.8m

Gross profit margin (FY, 2020), %

98.4%

Net income (FY, 2020)

(247.6m)

EBIT (FY, 2020)

(243.2m)

Market capitalization (14-Sept-2021)

1.6b

Closing stock price (14-Sept-2021)

26.3

Cash (31-Dec-2020)

494.8m

EV

1.5b
GBT (Global Blood Therapeutics)'s current market capitalization is $1.6 b.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

2.1m123.8m

Cost of goods sold

48.0k2.0m

Gross profit

2.1m121.8m

Gross profit Margin, %

98%98%
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

14.1m31.5m36.9m

Cost of goods sold

135.0k377.0k513.0k

Gross profit

14.0m31.1m36.4m

Gross profit Margin, %

99%99%99%
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

148.5m92.1m198.3m275.4m302.2m494.8m

Accounts Receivable

2.1m2.6m17.5m

Prepaid Expenses

3.8m6.3m4.7m949.0k

Inventories

1.3m40.2m
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

40.6m158.5m134.0m231.9m217.8m135.7m93.7m84.1m455.6m342.1m194.9m156.8m338.5m267.6m315.5m384.7m418.4m

Accounts Receivable

4.6m12.5m14.1m

Prepaid Expenses

419.0k1.6m1.9m1.6m1.7m4.0m5.0m10.4m10.3m7.1m9.0m8.2m8.2m12.7m14.1m13.5m14.8m

Inventories

14.9m27.3m33.8m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(46.4m)(82.5m)(117.0m)(174.2m)(266.8m)(247.6m)

Depreciation and Amortization

873.0k1.2m1.7m4.6m8.6m8.3m

Inventories

(1.3m)(36.8m)

Accounts Payable

2.7m1.1m2.8m(1.3m)4.5m8.4m
USDQ2, 2015

Financial Leverage

-0.7 x
Show all financial metrics

GBT (Global Blood Therapeutics) Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

GBT (Global Blood Therapeutics) Online and Social Media Presence

Embed Graph

GBT (Global Blood Therapeutics) News and Updates

Global Blood Therapeutics stock up 40% after FDA agrees to accelerated approval pathway for sickle cell disease drug

Shares of Global Blood Therapeutics Inc. shot up 40% Monday morning after the biotech company announced it had reached an agreement with the U.S. Food and Drug Administration to use an accelerated approval pathway for a potential sickle cell disease treatment. Voxelator, a once-a-day oral drug, wor…

Lifshitz & Miller LLP Announces Investigation of Access National Corporation, Engility Holdings, Inc., Floor & Decor Holdings, Inc., Global Blood Therapeutics, Inc., Intrexon Corporation, Keryx Biopharmaceuticals, Inc., Nevada Gold & Casinos, Inc., and Sonic Corp.

NEW YORK, Nov. 1, 2018 /PRNewswire/ -- Access National Corporation (ANCX) Lifshitz & Miller announces investigation into possible breaches of fiduciary duties in connection with the sale of ANCX to Union Bankshares Corporation for 0.75 shares of Union common stock per share. If you are an ...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Global Blood Therapeutics, Inc. - GBT

NEW YORK, Sept. 13, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Global Blood Therapeutics, Inc. ("Global Blood" or the "Company") (NASDAQ: GBT). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529,...

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Global Blood Therapeutics, Inc. (GBT)

NEW YORK, Sept. 13, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Global Blood Therapeutics, Inc. ("Global Blood" or the "Company") (NASDAQ: GBT). Such investors are encouraged to obtain...
Show more

GBT (Global Blood Therapeutics) Blogs

GBT and Sickle Cell Disease Association of America to Host 10th Annual Sickle Cell Disease (SCD) Therapeutics Conference

Centers for Medicare & Medicaid Services (CMS) Administrator Chiquita Brooks-LaSure to deliver keynote SOUTH SAN FRANCISCO, Calif. and BALTIMORE , Sept. 08, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) and the Sickle Cell Disease Association of America, Inc. (SCDA…

GBT Announces Participation at the Wedbush PacGrow Healthcare Conference

SOUTH SAN FRANCISCO, Calif. , Aug. 04, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics , Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the Wedbush PacGrow Healthcare Conference on Wednesday, August 11, 2021 , at 2:20 p.m. ET .

GBT Reports Second Quarter 2021 Financial Results

GBT Reports Second Quarter 2021 Financial Results Content Import Tue, 08/03/2021 - 16:08 GBT Reports Second Quarter 2021 Financial Results Aug 03, 2021 at 4:05 PM EDT This release is a backfill from a News Wire Earnings Achieved Oxbry…

GBT Reports First Quarter 2021 Financial Results

Achieved Oxbryta ® (voxelotor) net revenues of $39.0 million ; on track with plans to potentially expand access to Oxbryta in the U.S. and Europe       Advanced pipeline programs inclacumab and GBT021601 (GBT601) and expanded pipeline with in-license of two novel small molecule programs Conference

GBT to Announce First Quarter 2021 Financial Results on Wednesday, May 5, 2021

SOUTH SAN FRANCISCO, Calif. , April 28, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics , Inc. (GBT) (NASDAQ: GBT) today announced that it will report first quarter 2021 financial results on Wednesday, May 5, 2021 , after U.S. financial markets close.

GBT Opens 2021 ACCEL Grant Program, Providing up to $500,000 in Support to the Sickle Cell Disease Community

Grant proposals from community-based organizations and institutions accepted through April 23, 2021 SOUTH SAN FRANCISCO, Calif. , March 02, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics , Inc. (GBT) (NASDAQ: GBT) today announced that it is accepting proposals for the third annual Access to
Show more

GBT (Global Blood Therapeutics) Frequently Asked Questions

  • When was GBT (Global Blood Therapeutics) founded?

    GBT (Global Blood Therapeutics) was founded in 2012.

  • Who are GBT (Global Blood Therapeutics) key executives?

    GBT (Global Blood Therapeutics)'s key executives are Ted W. Love, Jung E. Choi and Jeffrey Farrow.

  • How many employees does GBT (Global Blood Therapeutics) have?

    GBT (Global Blood Therapeutics) has 352 employees.

  • What is GBT (Global Blood Therapeutics) revenue?

    Latest GBT (Global Blood Therapeutics) annual revenue is $123.8 m.

  • What is GBT (Global Blood Therapeutics) revenue per employee?

    Latest GBT (Global Blood Therapeutics) revenue per employee is $351.7 k.

  • Who are GBT (Global Blood Therapeutics) competitors?

    Competitors of GBT (Global Blood Therapeutics) include Acceleron Pharma, Ortho Dermatologics and Bath ASU.

  • Where is GBT (Global Blood Therapeutics) headquarters?

    GBT (Global Blood Therapeutics) headquarters is located at 171 Oyster Point Blvd #300South, South San Francisco.

  • Where are GBT (Global Blood Therapeutics) offices?

    GBT (Global Blood Therapeutics) has offices in South San Francisco and Zug.

  • How many offices does GBT (Global Blood Therapeutics) have?

    GBT (Global Blood Therapeutics) has 2 offices.